Marc Rubin
CIK 1412377 · Executive Chairman · last filed 2026-03-23
Marc Rubin is an Executive Chairman who has filed 67 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CRIS, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$476.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $48.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$48.1K
6
67
-$476.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRIS | Director | 28,108 | $0.42 | $11.8K | $55.3K | 22 | 2026-03-23 |
| GALT | Director | 13,581 | $2.67 | $36.3K | -$713.8K | 13 | 2025-01-27 |
| TITAN PHARMACEUTICALS INC (TTNP) Delisted | Executive Chairman | 556,317 | $4.61 | $2.56M | $116.2K | 10 | 2022-01-05 |
| GALECTIN THERAPEUTICS INC (GALTW) Delisted | Director | 17,446 | — | — | $26.1K | 4 | 2016-12-19 |
| MEDX | Director | — | $34.49 | — | $0 | 3 | 2009-03-09 |
| TITAN PHARMACEUTICALS INC (TTP) Delisted | President & Chief Ex Officer | 530,000 | $47.61 | $25.23M | $40.0K | 4 | 2008-10-22 |
Recent Filings
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-23 | CRIS | Conv (C) | +26,667 | $0 | EDGAR |
| 2026-03-18 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-01-30 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-01-27 | GALT | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2024-02-07 | GALT | Grant (A) | — | $0 | EDGAR |
| 2023-01-30 | GALT | Grant (A) | — | $0 | EDGAR |
| 2023-01-24 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2022-01-31 | CRIS | Grant (A) | — | $0 | EDGAR |